|
시장보고서
상품코드
1641385
세계의 측방유동 어세이 시장 : 주목 인사이트(2025-2030년)Global Lateral Flow Assays Market - Focused Insights 2025-2030 |
||||||
전 세계 측방유동 어세이 시장 규모는 2024년부터 2024년까지 CAGR 3.20%로 성장할 것으로 예상됩니다.
2024년에는 키트 및 시약 시장 부문이 가장 큰 시장 점유율을 차지했습니다. 이 분야의 성장은 주로 기술 개발 및 지속적인 발전에 기인합니다. 샌드위치 분석법은 여러 개의 결합 부위를 가진 더 큰 분석 대상을 검출하는 데 도움이 되기 때문에 3.56% 높은 성장세를 보이고 있습니다. 임상 진단 분야가 45% 가장 큰 점유율을 차지하고 있습니다. 임상 진단에서 측방유동 어세이의 적용은 만성 및 비만성질환의 유병률 증가로 인해 다른 산업에 비해 현저하게 높습니다. 병원 및 클리닉이 가장 큰 시장 점유율을 차지하고 있습니다. 병원 및 클리닉에서는 스크리닝, 진단, 모니터링, 예후 예측, 감시 등 다양한 용도로 LFA 기술이 사용되고 있으며, 이는 이 분야의 성장에 기여하고 있습니다.
2024년 북미는 전 세계 측방유동 어세이 시장에서 25% 이상의 가장 큰 점유율을 차지했습니다. 이 지역의 임상 진단, 환경 과학, 식품 산업 및 동물 의료 분야의 확립된 시장이 이러한 성장의 주요 원동력이 되고 있습니다. 세계 측방유동 어세이 시장은 LFA 리더의 개발, 스마트폰 및 AI의 LFA 통합에 대한 관심으로 인해 성장할 것으로 예상됩니다.
측방유동 어세이(LFA)은 수십 년 동안 임상 진단 및 환경 분야에서 널리 사용되어 온 현장 진단 플랫폼으로, 첨단 나노 소재의 적용은 LFA의 성능을 크게 향상시키고 다양한 응용 분야에서 물질 검출의 신뢰성을 향상시켜 업계를 선도하고 있습니다. LFA에 나노입자(NP)의 통합은 검출 한계 감소, 민감도 향상, 다중화, 분석물 정량화 등 현장 진단의 몇 가지 문제를 해결하는 데 도움이 됩니다. 현재 LFA 진단의 효율성과 편의성은 탄소 NP, 금 NP(Au NP), 양자점(QD), 업컨버젼 NP 등 광학 금속 나노입자를 사용하여 개선되고 있습니다. 이 중 금 나노입자(Au NPs)는 우수한 광학 특성과 화학적 안정성으로 인해 현재 가장 널리 사용되고 있으며, LFA에서 가장 많이 사용되는 광학 나노입자 중 하나입니다.
LFA의 새로운 기술과 시약은 공급업체에 의해 지속적으로 발전하고 있으며, 정확도와 감도를 향상시키고 있습니다. 또한, 광음향 기술, 표면 증강 라만 분광법(SERS), 스마트폰과 디지털 열 리더의 통합, 형광 공명 에너지 이동(FRET) 등 여러 신기술이 최근 시장에 등장하여 LFA 업계에서 유망하고 인기 있는 기술이 되었습니다. 이러한 기술은 LFA의 정확도를 높이고 민감도를 향상시켰으며, COVID-19 팬데믹 기간 동안 고감도 LFA에 대한 수요가 증가함에 따라 SERS 기술에 유리한 기회를 창출했습니다. 혈청 샘플의 높은 특이성으로 인해 SERS는 감염성 질환을 진단하는 효과적인 의료기기가 될 수 있습니다. 또한, 이 신기술은 휴대성, 디지털 분석, 30분 이내에 빠른 결과 제공, 여러 산업 응용 분야에서 다재다능함을 제공합니다.
세계의 측방유동 어세이 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 기술별, 용도별, 최종사용자별, 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.
The global lateral flow assay market is expected to grow at a CAGR of 3.20% from 2024 to 20230.
KEY TAKEAWAYS
MARKET OPPORTUNITIES & DRIVERS
Next-generation Lateral Flow Assay
Lateral flow assay (LFA) is a widely used point-of-care platform in clinical diagnostic and environmental applications from several decades ago. The adoption of advanced nanomaterials in LFAs is driving the industry forward by significantly enhancing their performance, making them more reliable for detecting substances in diverse applications. The integration of nanoparticles (NPs) in LAFs helps to address several challenges of point-of-care diagnostics, such as lowering the detection limits, sensitivity enhancement, multiplexing, and quantification of analytes. Currently, the efficiency and convenience of LFA diagnosis have been improved using some optical metal nanoparticles, such as carbon NPs, gold NPs (Au NPs), quantum dots (QD), and up-conversion NPs. Of these, owing to excellent optical properties and chemical stability, gold NPs (Au NPs) have now become the most popular and one of the most used optical nanometers in LFA.
Advancement in Lateral Flow Assay Solutions and Reagents
New technologies and reagents in LFAs are continuously advancing and improving accuracy and sensitivity by vendors. In addition, some new technologies have recently emerged in the market, such as photoacoustic techniques, Surface-enhanced Raman Spectroscopy (SERS), integration of smartphones and digital thermal readers, and fluorescence resonance energy transfer (FRET) have become promising and popular technologies in LFAs industry. These technologies are enabling more accuracy and increasing sensitivity of LFAs. During the COVID-19 pandemic, the increasing demand for high-sensitivity LFAs created lucrative opportunities for SERS technology. With high specificity in the serum sample, SERS becomes an effective medical device for diagnosing infectious diseases. Furthermore, this new technology offers more portability, digital analysis, rapid result delivery within 30 minutes, and versatility in use across several industrial applications.
Rising Acceptance of Point-of-care (POC) Testing
The point-of-care-testing (POCT) approach has expanded itself as having remarkable values in the diagnosis of infectious diseases as well as non-communicable diseases. Where, POCT has succeeded in meeting the current need for diagnostic strategies that can offer reliable, sensitive, fast, and highly accurate test results without incorporating complex procedures. This increasing demand has been accomplished by developing rapid bioanalytical sensors or tools such as Lateral Flow Assays (LFAs). The application of POCT in infectious disease diagnosis is well-known across the healthcare industry. However, its growing application in chronic diseases, such as cancer, stroke, diabetes, and Alzheimer's fuels significant market growth. The growing mortality of these non-communicable diseases drives the significant demand for POCT.
INDUSTRY RESTRAINTS
Limitations of Lateral Flow Assays
Lateral flow assay is a widely used solution across healthcare and other industries, and it gained high momentum in recent years. However, it also has some limitations, such as low resolution, they are unable to control the flow rate, and demand for large volumes of reagents creating huge imitations in their usage. Many LFIAs are designed for point-of-care/as-needed use, providing inexpensive, quick, and easy testing that is desirable in many industries. However, regulators often need to confirm results using independent methods. Therefore, LFIA is only suitable for primary point-of-care/as-needed screening. With a long shelf life and no refrigeration required for storage, these tests are well-suited for use in developing countries. Lateral flow (antigen) testing is widely used to enroll children in schools and kindergartens for SARS-CoV-2, the virus that causes COVID-19 infection. The accuracy of these tests in adults varies widely and is often much lower than specified by the manufacturer.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT
The global lateral flow assay market by product is segmented into kits & reagents and readers. The kits & reagents accounted for the largest market share in 2024. These kits and reagents, including biomarkers, assay kits, substrates, enzymes, specific proteins, lipids, and other test kits, are essential for obtaining quick and accurate results in diagnosing acute and chronic diseases. Segmental growth is primarily driven by continuous technological advancements, with lateral flow assay (LFA) kits becoming increasingly sophisticated through the integration of new technologies. These advancements create significant opportunities for market expansion. LFA kits are widely used for rapid and early detection of health conditions such as pregnancy, infectious diseases, blood glucose levels, and more. The rising prevalence of infectious and chronic diseases, coupled with the growing use of LFAs in women's health such as pregnancy and fertility testing contributes to the segment's robust growth.
By Product
INSIGHTS BY TECHNIQUE
The global lateral flow assay market by technique is categorized into sandwich assays and competitive assays. The sandwich assays show significant growth, with the fastest-growing CAGR of 3.56% during the forecast period. A sandwich assay is a non-competitive lateral flow assay commonly used to detect larger analytes with multiple binding sites. It is the most widely used assay technique in LFA. Some of its key applications include pregnancy test kits and COVID-19 rapid test kits. In the US, over 20 million pregnancy test kits are sold annually. In 2020, the World Health Organization facilitated the distribution of approximately 120 million COVID-19 rapid test kits globally. Furthermore, the sandwich assay is typically used to detect antigens from biological fluids, such as saliva, or pathogenic substances in food samples or genetically modified crops. Its wide range of applications spans human and veterinary clinical diagnostics, food safety, and the agriculture sector, driving significant growth in this segment.
By Technique
INSIGHTS BY APPLICATIONS
Based on the applications, the clinical diagnostics segment dominates and holds the largest share of the global lateral flow assay market in 2024. The application of lateral flow assays (LFAs) in clinical diagnostics is significantly higher compared to other industries. With the growing prevalence of chronic and non-chronic diseases, the demand for LFA-based point-of-care testing is continuously increasing across the global healthcare industry.
The use of LFAs for infectious disease diagnosis was well-established before the pandemic. However, the surge in COVID-19 infections has made LFAs one of the most critical tools in clinical diagnostics worldwide. The ability to rapidly diagnose infectious diseases has been identified as a strategic priority by various organizations. For instance, the Health and Human Services (HHS), the National Institutes of Health (NIH), the US Centers for Disease Control and Prevention (CDC), and the US Department of Defense (DoD) consider rapid and early detection essential to mitigating the impact of infectious diseases on populations.
By Applications
INSIGHTS BY END-USERS
Based on the end-users, in 2024, the hospitals and clinics segment holds the largest market share. In hospitals and clinics, the lateral flow assay (LFA) technique is used in a wide range of applications, including screening, diagnosis, monitoring, prognosis, and surveillance. Globally, the significant prevalence of various communicable and non-communicable diseases has led to an increasing demand for hospital admissions and clinical visits. From disease diagnosis to patient monitoring, LFAs play a vital role in supporting these operations. As an affordable, versatile, and reliable technique, LFAs are driving substantial market growth, with hospitals and clinics contributing significantly. Moreover, these facilities support clinical testing and research activities. Since hospitals are ideal settings for conducting clinical research, LFAs are commonly utilized in such environments. Additionally, hospital-associated diagnostics and pathology labs contribute significantly to market revenue growth. Nearly all hospitals have their clinical diagnostic labs, which generate a substantial demand for LFAs.
By End-Users
GEOGRAPHICAL ANALYSIS
In 2024, North America held the largest share of over 25% in the global lateral flow assay market. North America is a well-developed market for clinical diagnostics, environmental science, the food industry, and veterinary care, all of which significantly drive market growth in the region. The availability of advanced clinical diagnostic services and the widespread adoption of point-of-care testing strategies in the healthcare industry fuel the demand for LFAs. Self-diagnosis is a widely adopted approach in North America's healthcare sector. Beyond healthcare, industries such as environmental science, food production, and veterinary diagnostics also play major roles in driving market growth. In Canada, veterinary care is in high demand, while in the US, the veterinary industry is rapidly expanding due to increasing pet ownership and a growing population of farm animals. The food industry is also experiencing significant growth in both the US and Canada. This growth, coupled with stringent food safety regulations, has created a substantial demand for LFAs in food safety testing. As the food industry expands, regulatory norms continue to tighten to ensure food safety, further boosting the need for lateral flow assays.
By Geography
COMPETITIVE LANDSCAPE
The global lateral flow assays market report consists of exclusive data on 36 vendors. Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, QuidelOrtho Corporation, and PerkinElmer are some of the leading companies accounting for the largest share of the global lateral flow assays market. These vendors are continuously focusing on expanding their lateral flow assay solutions and services that meet customers' requirements and international regulations, as well as increasing the efficiency of their products and strengthening their market position. Also, the adoption of various strategies, such as product launches, and new product development with advanced technologies, by key and other prominent players intensified the competition in the market. The adoption of such strategies by the major market players and their focus on expanding their capabilities have enabled them to gain a higher revenue share in the market. In 2024, Gold Standard Diagnostics announced the launch of a new allergen PowerLine Test: SENSIStrip Gluten Powerline Lateral Flow Device for food safety applications.
Key Vendors
Other Prominent Vendors
KEY QUESTIONS ANSWERED:
CHAPTER - 1: Competitive Landscape of Lateral Flow Assays Market Overview
CHAPTER - 2: Competitive Landscape of Lateral Flow Assays Market
CHAPTER - 3: Lateral Flow Assays Market Prospects & Opportunities
CHAPTER - 4:Lateral Flow Assays Market Segmentation Data
CHAPTER - 5: Key Regions Overview
CHAPTER - 6: Lateral Flow Assays Market Industry Overview
CHAPTER - 7: Appendix